p21Cip1 confers resistance to imatinib in human chronic myeloid leukemia cells. | | p21Cip1 confers resistance to imatinib in human chronic myeloid leukemia cells. | Ferrandiz, N, Caraballo, J. M., Albajar, M, Gomez-Casares, M.T., López-Jorge, C.E., Blanco, R., Delgado, M.D. and Leon, J. Cancer Lett 292: 133-139 (2010). | 2010-06-14T22:00:00Z | <p style="text-align:justify;"><span class="ms-rteThemeForeColor-2-5"><span style="font-family:arial, helvetica, clean, sans-serif;font-size:1.0769em;font-weight:bold;">Abstract</span></span></p><div style="color:#000000;font-family:arial, helvetica, clean, sans-serif;text-align:justify;"><p style="margin-bottom:0.5em;font-size:1.04em;">Imatinib is a Bcr-Abl inhibitor used as first-line therapy of chronic myeloid leukemia (CML). p21(Cip1), initially described as a cell cycle inhibitor, also protects from apoptosis in some models. We describe that imatinib down-regulates p21(Cip1) expression in CML cells. Using K562 cells with inducible p21 expression and transient transfections we found that p21 confers partial resistance to imatinib-induced apoptosis. This protection is not related to the G2-arrest provoked by p21, a decrease in the imatinib activity against Bcr-Abl or a cytoplasmic localization of p21. The results suggest an involvement of p21(Cip1) in the response to imatinib in CML.<br></p></div> | <p><span class="ms-rteForeColor-2"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20042273">[pubmed]</a></span><br></p> | 107 | | |